Prioritization of putatively detrimental variants in euploid miscarriages - Buonaiuto, Silvia; Di Biase, Immacolata; Aleotti, Valentina; Ravaei, Amin; Marino, Adriano De; Damaggio, Gianluca; Chierici, Marco; Pulijala, Madhuri; D’Ambrosio, Palmira; Esposito, Gabriella; Ayub, Qasim; Furlanello, Cesare; et al. (medRxiv, 2021)
Miscarriage is the spontaneous termination of a pregnancy before 24 weeks of gestation. We studied the genome of euploid miscarried embryos from mothers in the range of healthy adult individuals to understand genetic susceptibility to miscarriage not caused by chromosomal aneuploidies. We developed GP, a pipeline that we used to prioritize 439 unique variants in 399 genes, including genes known to be associated with miscarriages. Among the prioritized genes we found STAG2 coding for the cohesin complex subunit, for which inactivation in mouse is lethal, and TLE4 a target of Notch and Wnt, physically interacting with a region on chromosome 9 associated to miscarriages.Competing Interest StatementA.C. is a full time employee of Igenomix. A.D.M. was employee of Igenomix while working on this project. I.D.B.,P.D.A., G.E., S.D.B. are full time employees of the MeriGen Research. All other authors declare that they have no conflicts of interest.Funding StatementP.O.R. Campania FSE 2014-2020 and EMBO STF 7919 to V.C. The computational work has been executed on the IT resources of the ReCaS-Bari data center, which have been made available by two projects financed by the MIUR (Italian Ministry for Education, University and Research) in the PON Ricerca e Competitivita 2007-2013 Program: ReCaS (Azione I - Interventi di rafforzamento strutturale, PONa3 00052, Avviso 254/Ric) and PRISMA (Asse II - Sostegno all innovazione, PON04a2 A)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was examined by the Comitato Etico di Area Vasta Emilia Centro (CE-AVEC) of the Azienda Ospedaliero - Universitaria di Bologna Policlinico S. Orsola-Malpighi in Bologna, Italy. The committee gave the ethical approval of the study (reference CE/FE 170475).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available through collaboration